A sale of the medical distribution business could increase Henry Schein's (HSIC) shares by 20%, while EPS could jump by ~35% ...

Activist investor Ananym Capital Management is urging healthcare products distributor Henry Schein to refresh its board, cut costs, tackle succession planning and consider selling its medical ...

Activist Ananym Capital Management is urging Henry Schein (HSIC) to refresh its board, cut costs, tackle succession planning and consider selling its medical distribution business, Svea Herbst-Bayliss ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $79.5, a high estimate of $82.00, ...

Henry Schein ( (HSIC) ) has released its Q3 earnings. Here is a breakdown of the information Henry Schein presented to its investors. Henry ...

Analysts' ratings for Henry Schein (NASDAQ:HSIC ... products and services primarily to office-based dental and medical practitioners, as well as alternate sites of care. The company operates ...

Yes. So if you look at the medical market for Henry Schein, you put aside the ups and downs of the flu season, whether it's vaccines, COVID, and general flu vaccine, those may shift up or down ...

We recently made a list of UBS’ Bottom Quant Stocks In AI, IT, Healthcare & Others: 29 Stocks In All Sectors. In this piece, ...

Henry Schein has finally disclosed a data breach following at least two back-to-back cyberattacks in 2023 by the BlackCat Ransomware gang, revealing that over 160,000 people had their personal ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Henry Schein is a Fortune 500 company and one of the global leaders in its industry, providing healthcare solutions, as well as the distribution of medical, dental, and veterinary supplies.